Lebanon vs Malaysia: Statin use vs. average non-HDL cholesterol levels
Lebanon
3.9
in 2018
Malaysia
4.2
in 2018
Lebanon rank
4th
Malaysia rank
1st
Statin use vs. average non-HDL cholesterol levels over time
- Lebanon
- Malaysia
How they compare
Malaysia currently reports 4.2 against 3.9 in Lebanon, a difference of 0.3.
That makes Malaysia's figure about 1.1 times Lebanon's.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Lebanon ahead.
Lebanon ranks 4th and Malaysia ranks 1st of 191 countries.
Across the 4 decades both report, Lebanon averaged higher in 2 and Malaysia in 2.
Head to head by decade
| Decade | Lebanon | Malaysia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.06 | 3.67 | 0.39 | Lebanon |
| 1990s | 4.1 | 3.84 | 0.26 | Lebanon |
| 2000s | 4 | 4.09 | 0.09 | Malaysia |
| 2010s | 3.9 | 4.2 | 0.3 | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Lebanon or Malaysia?
- Malaysia, at 4.2 against 3.9 in Lebanon as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Lebanon and Malaysia?
- 0.3, with Malaysia ahead.
- How many years of comparable data are there for Lebanon and Malaysia?
- 39 years are reported by both, from 1980 to 2018.
- How do Lebanon and Malaysia rank globally for statin use vs. average non-hdl cholesterol levels?
- Lebanon ranks 4th and Malaysia ranks 1st of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.